You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

Article info

Article menu

Download PDFPDF

Case Report
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

Authors

  • Jared R. Lowe Department of MedicineDuke University Medical Center 27710 Durham NC USA PubMed articlesGoogle scholar articles
  • Daniel J. Perry Department of Pathology, Immunology, and Laboratory MedicineUniversity of Florida College of Medicine 32610 Gainesville FL USA PubMed articlesGoogle scholar articles
  • April K. S. Salama Department of Medicine, Division of Medical Oncology, Melanoma Program, Duke Cancer InstituteDuke University Medical Center 27710 Durham NC USA PubMed articlesGoogle scholar articles
  • Clayton E. Mathews Department of Pathology, Immunology, and Laboratory MedicineUniversity of Florida College of Medicine 32610 Gainesville FL USA PubMed articlesGoogle scholar articles
  • Larry G. Moss Department of Medicine, Division of Endocrinology, Metabolism, & NutritionDuke University Medical Center, Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center 27701 Durham NC USA PubMed articlesGoogle scholar articles
  • Brent A. Hanks Department of Medicine, Division of Medical Oncology, Melanoma Program, Duke Cancer InstituteDuke University Medical Center 27710 Durham NC USA PubMed articlesGoogle scholar articles
  1. ↵a jared.lowe{at}duke.edu
  2. ↵b perryd{at}pathology.ufl.edu
  3. ↵c april.salama{at}duke.edu
  4. ↵d clayton.mathews{at}pathology.ufl.edu
  5. ↵e larry.moss{at}duke.edu
  6. ↵f hanks004{at}mc.duke.edu
View Full Text

Citation

Lowe JR, Perry DJ, Salama AKS, et al
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Journal for ImmunoTherapy of Cancer 2016;4:89. doi: 10.1186/s40425-016-0196-z

Publication history

  • Received August 15, 2016
  • Accepted November 17, 2016
  • First published December 20, 2016.
Online issue publication 
February 15, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.